Abstract | OBJECTIVES:
Vestibular schwannomas are the hallmark of neurofibromatosis type two. They are difficult to treat, due to their bilateral presentation and the quest for hearing preservation. Our report describes a new treatment approach in this clinical scenario. CASE REPORT: CONCLUSION:
|
Authors | G K Eminowicz, R Raman, J Conibear, P N Plowman |
Journal | The Journal of laryngology and otology
(J Laryngol Otol)
Vol. 126
Issue 1
Pg. 79-82
(Jan 2012)
ISSN: 1748-5460 [Electronic] England |
PMID | 22004800
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Contrast Media
- Vascular Endothelial Growth Factors
- Bevacizumab
- Gadolinium
|
Topics |
- Adult
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Humanized
(administration & dosage, therapeutic use)
- Bevacizumab
- Contrast Media
- Female
- Gadolinium
- Hearing Loss, Unilateral
(etiology, prevention & control)
- Humans
- Magnetic Resonance Imaging
- Male
- Neurofibromatosis 2
(complications, drug therapy, radiotherapy, surgery)
- Neuroma, Acoustic
(drug therapy, etiology, radiotherapy, surgery)
- Radiosurgery
(instrumentation)
- Remission Induction
(methods)
- Treatment Outcome
- Vascular Endothelial Growth Factors
|